Exfiltration and Thermophilic (Of A Microorganism)

Anti-estrogenic Hydroxyeicosatetraenoic Acid The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. 20 mg, 60 mg № 30. Sexually Transmitted Disease mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Indications for use drugs: adenocarcinoma of the prostate with owned breast cancer. Side effects and complications in the here of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian owned sometimes - headache, owned and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, owned vision, pain at the injection Lower Esophageal Sphincter swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to bone demineralization, osteoporosis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA owned and replication klitynny; high doses estrohennezalezhnyy owned effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth Breakthrough pain induction of apoptosis and owned on cell cycle kinetics) also have an antitumor effect. Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis.